Cannabix Targets Combat Sports Market for Commercial Rollout of Marijuana Breath Test at ABC Boxing & MMA Conference

Vancouver, British Columbia, August 4, 2026 -- Cannabix Technologies Inc. (CSE: BLO) (OTCID: BLOZF) (Frankfurt: 8CT) (the “Company” or “Cannabix”), a developer of marijuana and alcohol breath testing technologies for workplace and public safety is pleased to announce that its Marijuana Breath Test ("MBT") technology has been invited for presentation at the Association of Boxing Commissions and Combative Sports ("ABC") 38th Annual Conference, to be held at the Caribe Royale Resort in Orlando, Florida in August. The conference is recognized as one of the leading gatherings of combat sports regulators, athletic commissioners, medical professionals, referees, judges, inspectors, and industry stakeholders involved in professional boxing, mixed martial arts (MMA) and other combative sports.

The ABC Annual Conference gives Cannabix and its strategic laboratory partner, Omega Laboratories, direct access to regulators and organizations responsible for athlete safety, pre-event screening, post-incident evaluation and cannabis-related testing policies across professional boxing, mixed martial arts (MMA), Muay Thai and other combative sports.

The Marijuana Breath Test technology is a new tool for boxing and MMA organizations seeking objective methods to assess recent marijuana use among athletes participating in safety-sensitive activities (Figure 1). Cannabix believes the combat sports market represents a commercialization opportunity because athletic commissions, sanctioning bodies and promoters face an immediate need for objective and non-invasive tools to assess recent cannabis use in safety-sensitive settings. Combat sports involve split-second decision making, reaction time, hand-eye coordination, balance, situational awareness and athlete safety. Unlike traditional specimen testing that can detect cannabis use long after potential effects have subsided, breath-based THC testing is designed to focus on recent use closer to the time of competition, training or incident review.

As cannabis regulations continue to evolve across North America and internationally, athletic commissions and sanctioning organizations are increasingly faced with the challenge of balancing athlete rights, public safety and competitive integrity. Cannabix believes recent-use breath testing can provide commissions with a more practical and relevant tool to support cannabis-related decisions before events, after incidents and in regulated athlete safety programs.

The MBT platform is designed to support customer adoption by offering combat sports regulators and promoters a testing workflow with several practical benefits, including:

• Recent-use THC information closer to competition, training or incident timing
• Rapid, non-invasive breath collection
• A practical pre-event and post-incident screening workflow
• Laboratory-supported confirmation through Omega Laboratories
• More consistent cannabis-related decision-making for regulators
• Expandable platform potential for broader drug panels and additional safety-sensitive markets

Cannabix is also advancing broader breath-based drug detection capabilities, including work toward a 5-panel breath testing platform for multiple drug classes. The Company believes this broader capability could expand commercial applicability beyond cannabis-only testing and support a wider range of safety-sensitive markets, including sports regulation, workplace safety, law enforcement, corrections, transportation and incident-response programs. A multi-panel breath testing solution, combined with laboratory confirmation capabilities, could provide organizations with a more comprehensive and modern testing framework than currently available through traditional specimen collection methods.

Jerry Crosby, President of Omega Laboratories, Inc., will lead Cannabix’s technical and commercial discussions at the conference. Omega Laboratories will support the engagement with forensic drug testing expertise, laboratory confirmation capabilities and real-world testing experience. Omega’s involvement strengthens the commercial pathway for Cannabix by pairing the Company’s breath collection technology with an established laboratory partner capable of supporting confirmatory testing, customer implementation and regulated testing workflows.

“The value of breath testing is that it can provide more time relevant information than traditional testing methods in settings where drug use timing matters,” said Jerry Crosby, President of Omega Laboratories. “For combat sports, where athlete safety, reaction time and medical decision-making are critical, recent-use testing supported by laboratory confirmation can give regulators a more practical tool for cannabis-related evaluations.”

“Combat sports regulators and athletic commissions are looking for practical tools that improve athlete safety while addressing the realities of evolving cannabis laws. Engaging the Marijuana Breath Test directly with this audience allows us to reach potential end users, demonstrate the value of recent-use breath testing and advance discussions around real-world deployment.”, said Rav Mlait, CEO of Cannabix Technologies.

The ABC Conference is part of Cannabix’s broader commercialization strategy to move its breath testing technology from development and validation into targeted market engagement with organizations that have defined safety, regulatory and testing needs. Cannabix is initially focusing on markets where recent-use detection, rapid collection and defensible testing decisions can provide a clear operational advantage.